Edition:
United States

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

34.75USD
20 Aug 2018
Change (% chg)

-- (--)
Prev Close
$34.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
376,152
52-wk High
$86.22
52-wk Low
$33.92

Latest Key Developments (Source: Significant Developments)

Clovis Oncology Announces European Commission Authorization Of Rubraca
Tuesday, 29 May 2018 08:00am EDT 

May 29 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES EUROPEAN COMMISSION AUTHORIZATION OF RUBRACA® (RUCAPARIB) FOR WOMEN WITH RECURRENT OVARIAN CANCER.CLOVIS ONCOLOGY INC - EC APPROVAL WAS BASED ON DATA FROM TWO MULTICENTER, SINGLE-ARM, OPEN-LABEL CLINICAL TRIALS.  Full Article

Clovis Oncology Reports Q1 Loss Per Share $1.54
Tuesday, 8 May 2018 04:05pm EDT 

May 8 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2018 OPERATING RESULTS.Q1 LOSS PER SHARE $1.54.Q1 EARNINGS PER SHARE VIEW $-1.36 -- THOMSON REUTERS I/B/E/S.QTRLY PRODUCT REVENUE $18.5 MILLION VERSUS $7 MILLION.  Full Article

Clovis Oncology Says SEC Issued 'Wells Notices' To Co & Certain Of Its Officers
Tuesday, 10 Apr 2018 09:35am EDT 

April 10 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY SAYS ON APRIL 9 SEC ISSUED 'WELLS NOTICES' TO CO & CERTAIN OF ITS CURRENT AND FORMER OFFICERS - SEC FILING.SEC'S 'WELLS NOTICES' ALLEGES VIOLATIONS OF SOME PROVISIONS OF SECURITIES ACT OF 1933 AND SECURITIES EXCHANGE ACT OF 1934.ALLEGED VIOLATIONS RELATE TO CO'S REGULATORY UPDATE IN NOV 2015 THAT FDA REQUESTED MORE CLINICAL DATA ON EFFICACY, SAFETY OF ROCILETINIB.  Full Article

EMA Panel Recommends Conditional Approval Of Clovis Oncology Ovarian Cancer Drug Rubraca
Friday, 23 Mar 2018 08:52am EDT 

March 23 (Reuters) - EU Medicines Agency: :RECOMMENDS APPROVAL OF CLOVIS ONCOLOGY <<>> OVARIAN CANCER DRUG RUBRACA.EU MEDICINES AGENCY SAYS RECOMMENDED GRANTING A CONDITIONAL MARKETING AUTHORISATION FOR CLOVIS OVARIAN CANCER DRUG RUBRACA.  Full Article

Clovis Oncology Q4 Adjusted Loss Per Share $1.27
Monday, 26 Feb 2018 04:05pm EST 

Feb 26 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES 2017 OPERATING RESULTS.Q4 ADJUSTED LOSS PER SHARE $1.27 EXCLUDING ITEMS.Q4 LOSS PER SHARE $1.04.QTRLY ‍​NET PRODUCT REVENUE $17 MILLION VERSUS $78,000.Q4 REVENUE VIEW $20.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Clovis Oncology Receives Positive Trend Vote In European Regulatory Review Ovarian Cancer Treatment
Wednesday, 21 Feb 2018 05:10pm EST 

Feb 21 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY RECEIVES POSITIVE TREND VOTE FROM CHMP IN EUROPEAN REGULATORY REVIEW FOR RUCAPARIB OVARIAN CANCER TREATMENT INDICATION.CLOVIS ONCOLOGY INC - PENDING A POSITIVE RECOMMENDATION BY CHMP FOR RUCAPARIB TABLETS, FINAL APPROVAL BY EUROPEAN COMMISSION WOULD FOLLOW IN Q2 2018.  Full Article

Clovis Oncology reports Q3 adjusted shr loss of $1.24
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Clovis Oncology Inc -:CLOVIS ONCOLOGY ANNOUNCES THIRD QUARTER 2017 OPERATING RESULTS.Q3 ADJUSTED LOSS PER SHARE $1.24 EXCLUDING ITEMS.Q3 LOSS PER SHARE $1.24.Q3 EARNINGS PER SHARE VIEW $-1.22 -- THOMSON REUTERS I/B/E/S.  Full Article

Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet
Wednesday, 13 Sep 2017 06:00am EDT 

Sept 13 (Reuters) - Clovis Oncology Inc :Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet.Study successfully achieved primary, key secondary and exploratory endpoints​.Plans to submit supplemental new drug application in U.S. for maintenance treatment indication in ovarian cancer by end of Oct 2017​.In early 2018, plans to file MAA in Europe for maintenance treatment indication upon receipt of potential approval for treatment indication​.  Full Article

Clovis Oncology Q2 loss per share $3.88
Wednesday, 2 Aug 2017 04:05pm EDT 

Aug 2 (Reuters) - Clovis Oncology Inc ::Clovis Oncology announces second quarter 2017 operating results.Q2 loss per share $3.88.Q2 earnings per share view $-2.13 -- Thomson Reuters I/B/E/S.  Full Article

Bristol-Myers, Clovis Oncology announce broad clinical collaboration
Monday, 31 Jul 2017 06:59am EDT 

July 31 (Reuters) - Bristol-Myers Squibb Co ::Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration to evaluate combination of opdivo (nivolumab) and rubraca (rucaparib) in phase 2 and pivotal phase 3 clinical trials in multiple tumor types.Bristol-Myers Squibb Co says specific terms of agreement were not disclosed.Bristol-Myers Squibb Co - specific terms of agreement were not disclosed.Bristol-Myers Squibb Co - ‍all three studies are expected to begin before end of 2017​.Bristol-Myers Squibb - phase 2 trial to evaluate opdivo in combination with rubraca, other compounds in metastatic castration-resistant prostate cancer.Bristol-Myers Squibb Co says planned multi-arm clinical trials will be conducted in U.S., Europe, and possibly additional countries.Bristol-Myers Squibb - phase 3 trials planned for 2017 will evaluate rubraca in combination with opdivo, rubraca as monotherapy, & opdivo as monotherapy.Bristol-Myers Squibb Co - ‍clovis will be study sponsor and conducting party for ovarian cancer study​.Bristol-Myers Squibb - collaboration will also include phase 2 study to evaluate safety and efficacy of opdivo in combination with rubraca.  Full Article

BRIEF-Clovis Oncology Reports Q1 Loss Per Share $1.54

* CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2018 OPERATING RESULTS